Sensei Biotherapeutics (NASDAQ:FTH) Research Coverage Started at Needham & Company LLC

Needham & Company LLC initiated coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research note issued to investors on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $56.00 target price on the stock.

Several other brokerages have also recently weighed in on FTH. Weiss Ratings started coverage on Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Oppenheimer started coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Wall Street Zen raised shares of Sensei Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Price Performance

Shares of FTH stock opened at $32.00 on Friday. The company’s 50 day simple moving average is $27.27. The stock has a market cap of $826.88 million, a PE ratio of -0.23 and a beta of -0.25. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. On average, sell-side analysts anticipate that Sensei Biotherapeutics will post -13.18 EPS for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In related news, CFO Brian C. Stephenson bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was bought at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the transaction, the chief financial officer owned 46,688 shares of the company’s stock, valued at approximately $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the transaction, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 49,494 shares of company stock valued at $1,188,822. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors have recently modified their holdings of FTH. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after buying an additional 1,100 shares in the last quarter. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the first quarter worth approximately $4,188,000. Bank of America Corp DE boosted its stake in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares in the last quarter. Vivo Capital LLC bought a new position in Sensei Biotherapeutics during the first quarter valued at approximately $22,758,000. Finally, Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics during the second quarter valued at approximately $3,610,000. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.